<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03474601</url>
  </required_header>
  <id_info>
    <org_study_id>1503-040-654</org_study_id>
    <nct_id>NCT03474601</nct_id>
  </id_info>
  <brief_title>Seoul National University Pituitary Disease Cohort Study</brief_title>
  <acronym>SNU-PIT</acronym>
  <official_title>Seoul National University Pituitary Disease Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the treatment and natural history of pituitary
      disease. We have a longstanding interest in pituitary disease including acromegaly, central
      diabetes insipidus, and nonfunctioning pituitary adenoma. We will continue to follow patients
      and recruit new patients for treatment and follow-up. Blood and pituitary tumor tissue (when
      available through clinical care) will be saved for future analyses related to pituitary
      disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects for this study will be recruited if they are:

        1. Adults, male or female aged 18 years or older

        2. Have been diagnosed with pituitary diseases
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2015</start_date>
  <completion_date type="Anticipated">February 14, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 14, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment outcome of pituitary diseases</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Remission rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications of pituitary disease</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Visual field defect or hypopituitarism, hormone hyperfunction-related complications</description>
  </secondary_outcome>
  <number_of_groups>8</number_of_groups>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>Pituitary Disease</condition>
  <condition>Pituitary Incidentaloma</condition>
  <condition>Acromegaly</condition>
  <condition>Central Diabetes Insipidus</condition>
  <condition>Pituitary Stalk Compression Hyperprolactinaemia</condition>
  <condition>Cushing's Disease</condition>
  <condition>Pituitary Tumor</condition>
  <condition>Prolactinoma</condition>
  <arm_group>
    <arm_group_label>Acromegaly</arm_group_label>
    <description>Patients diagnosed with acromegaly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cushing's disease</arm_group_label>
    <description>Patients diagnosed with Cushing's disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyperprolactinemia/prolactinomas</arm_group_label>
    <description>Patients diagnosed with hyperprolactinemia/prolactinoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pituitary stalk lesions</arm_group_label>
    <description>Patients diagnosed with pituitary stalk lesions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nonfunctioning pituitary adenomas</arm_group_label>
    <description>Patients diagnosed with nonfunctioning pituitary adenomas</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Central diabetes insipidus</arm_group_label>
    <description>Patients diagnosed with central diabetes insipidus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Craniopharyngioma</arm_group_label>
    <description>Patients diagnosed with craniopharyngiomas</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Others</arm_group_label>
    <description>Patients diagnosed with other suprasellar/parasellar lesions</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dynamic hormone study and Magnetic resonance imaging</intervention_name>
    <description>Medical history
Imaging examination including brain magnetic resonance imaging
Blood (Basal hormone study and follow-up study) and pituitary tumor tissue</description>
    <arm_group_label>Acromegaly</arm_group_label>
    <arm_group_label>Cushing's disease</arm_group_label>
    <arm_group_label>Hyperprolactinemia/prolactinomas</arm_group_label>
    <arm_group_label>Pituitary stalk lesions</arm_group_label>
    <arm_group_label>Nonfunctioning pituitary adenomas</arm_group_label>
    <arm_group_label>Central diabetes insipidus</arm_group_label>
    <arm_group_label>Craniopharyngioma</arm_group_label>
    <arm_group_label>Others</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood Pituitary tumor tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with pituitary disease at Seoul National University Hospital
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects for this study will be recruited if they are:

               1. Adults, male or female aged 18 years or older

               2. diagnosed with pituitary diseases such as acromegaly, Cushing's disease,
                  hyperprolactinemia, nonfunctioning pituitary adenoma, pituitary stalk lesions,
                  central diabetes insipidus, and craniopharyngiomas

        Exclusion Criteria:

          -  Patients who do not agree with the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jung Hee Kim, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jung Hee Kim, M.D</last_name>
    <phone>82-2-2072-4073</phone>
    <email>jhkxingfu@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jung Hee Kim, M.D</last_name>
      <email>jhkxingfu@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2018</study_first_submitted>
  <study_first_submitted_qc>March 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2018</study_first_posted>
  <last_update_submitted>March 15, 2018</last_update_submitted>
  <last_update_submitted_qc>March 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jung Hee Kim</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pituitary Diseases</keyword>
  <keyword>Pituitary incidentaloma</keyword>
  <keyword>Central Diabetes Insipidus</keyword>
  <keyword>Pituitary Neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pituitary Diseases</mesh_term>
    <mesh_term>Acromegaly</mesh_term>
    <mesh_term>Pituitary Neoplasms</mesh_term>
    <mesh_term>Pituitary ACTH Hypersecretion</mesh_term>
    <mesh_term>ACTH-Secreting Pituitary Adenoma</mesh_term>
    <mesh_term>Hyperprolactinemia</mesh_term>
    <mesh_term>Diabetes Insipidus</mesh_term>
    <mesh_term>Prolactinoma</mesh_term>
    <mesh_term>Diabetes Insipidus, Neurogenic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Arginine Vasopressin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

